drugset / Trial / NCT01068756

Effect of Rifampin on the Pharmacokinetics of Dapagliflozin in Healthy Subjects

NCT01068756

Phase 1 Terminated 14 enrolled AstraZeneca Bristol-Myers Squibb · collab
NaSingle-groupOpen-label

Summary

The purpose of the study is to assess the effects of rifampin on the pharmacokinetics of dapagliflozin

Timeline

Start
2010-03
Primary completion
2010-04
Completion
2010-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Dapagliflozin Small molecule 10 mg Oral
Subject Rifampin Small molecule 600 mg Oral